KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Revenue (2016 - 2026)

Pacific Biosciences Of California has reported Revenue over the past 16 years, most recently at $44.6 million for Q4 2025.

  • For Q4 2025, Revenue rose 13.82% year-over-year to $44.6 million; the TTM value through Dec 2025 reached $160.0 million, up 3.89%, while the annual FY2025 figure was $160.0 million, 3.89% up from the prior year.
  • Revenue for Q4 2025 was $44.6 million at Pacific Biosciences Of California, up from $38.4 million in the prior quarter.
  • Over five years, Revenue peaked at $58.4 million in Q4 2023 and troughed at $27.4 million in Q4 2022.
  • A 5-year average of $38.9 million and a median of $38.4 million in 2025 define the central range for Revenue.
  • Biggest five-year swings in Revenue: soared 113.35% in 2023 and later crashed 32.79% in 2024.
  • Year by year, Revenue stood at $36.0 million in 2021, then fell by 24.06% to $27.4 million in 2022, then skyrocketed by 113.35% to $58.4 million in 2023, then crashed by 32.79% to $39.2 million in 2024, then increased by 13.82% to $44.6 million in 2025.
  • Business Quant data shows Revenue for PACB at $44.6 million in Q4 2025, $38.4 million in Q3 2025, and $39.8 million in Q2 2025.